155 related articles for article (PubMed ID: 31855950)
1. Immunohistochemical Markers With Potential Diagnostic, Prognostic, and Therapeutic Significance in Uterine Carcinosarcoma: A Clinicopathologic Study of 43 Cases.
Jones TE; Pradhan D; Dabbs DJ; Bhargava R; Onisko A; Jones MW
Int J Gynecol Pathol; 2021 Jan; 40(1):84-93. PubMed ID: 31855950
[TBL] [Abstract][Full Text] [Related]
2. HER2 Overexpression and Amplification in Uterine Carcinosarcomas With Serous Morphology.
Jenkins TM; Cantrell LA; Stoler MH; Mills AM
Am J Surg Pathol; 2022 Apr; 46(4):435-442. PubMed ID: 35125452
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expression in uterine carcinosarcoma.
Kucukgoz Gulec U; Kilic Bagir E; Paydas S; Guzel AB; Gumurdulu D; Vardar MA
Eur J Obstet Gynecol Reprod Biol; 2020 Jan; 244():51-55. PubMed ID: 31739121
[TBL] [Abstract][Full Text] [Related]
4. Uterine Carcinosarcomas: Clinical, Histopathologic and Immunohistochemical Characteristics.
Chen X; Arend R; Hamele-Bena D; Tergas AI; Hawver M; Tong GX; Wright TC; Wright JD
Int J Gynecol Pathol; 2017 Sep; 36(5):412-419. PubMed ID: 28700424
[TBL] [Abstract][Full Text] [Related]
5. Molecular markers and clinical behavior of uterine carcinosarcomas: focus on the epithelial tumor component.
de Jong RA; Nijman HW; Wijbrandi TF; Reyners AK; Boezen HM; Hollema H
Mod Pathol; 2011 Oct; 24(10):1368-79. PubMed ID: 21572397
[TBL] [Abstract][Full Text] [Related]
6. PD-L1 Expression in Carcinosarcomas of the Gynecologic Tract: A Potentially Actionable Biomarker.
Pinto A; Mackrides N; Nadji M
Appl Immunohistochem Mol Morphol; 2018 Jul; 26(6):393-397. PubMed ID: 27801734
[TBL] [Abstract][Full Text] [Related]
7. PD-L1 and Mismatch Repair Status in Uterine Carcinosarcomas.
Jenkins TM; Cantrell LA; Stoler MH; Mills AM
Int J Gynecol Pathol; 2021 Nov; 40(6):563-574. PubMed ID: 33323859
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors and status of hormone receptors and angiogenic factors in uterine carcinosarcoma.
Etoh T; Nakai H
J Obstet Gynaecol Res; 2014 Mar; 40(3):820-5. PubMed ID: 24320058
[TBL] [Abstract][Full Text] [Related]
9. [Clinicopathological and gene mutation characteristics of uterine carcinosarcoma].
Tu J; Xu JZ; Zhang YS; Deng LF
Zhonghua Yi Xue Za Zhi; 2023 Jun; 103(24):1864-1867. PubMed ID: 37357193
[TBL] [Abstract][Full Text] [Related]
10. Uterine carcinosarcoma and high-risk endometrial carcinomas: a clinicopathological comparison.
Zhang C; Hu W; Jia N; Li Q; Hua K; Tao X; Wang L; Feng W
Int J Gynecol Cancer; 2015 May; 25(4):629-36. PubMed ID: 25633654
[TBL] [Abstract][Full Text] [Related]
11. Rare uterine cancer: carcinosarcomas. Review from histology to treatment.
Artioli G; Wabersich J; Ludwig K; Gardiman MP; Borgato L; Garbin F
Crit Rev Oncol Hematol; 2015 Apr; 94(1):98-104. PubMed ID: 25468677
[TBL] [Abstract][Full Text] [Related]
12. Uterine carcinosarcoma: Contemporary clinical summary, molecular updates, and future research opportunity.
Matsuzaki S; Klar M; Matsuzaki S; Roman LD; Sood AK; Matsuo K
Gynecol Oncol; 2021 Feb; 160(2):586-601. PubMed ID: 33183764
[TBL] [Abstract][Full Text] [Related]
13. Histologic Appearance and Immunohistochemistry of DNA Mismatch Repair Protein and p53 in Endometrial Carcinosarcoma: Impact on Prognosis and Insights Into Tumorigenesis.
Saijo M; Nakamura K; Ida N; Nasu A; Yoshino T; Masuyama H; Yanai H
Am J Surg Pathol; 2019 Nov; 43(11):1493-1500. PubMed ID: 31478942
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological characteristics, treatment and outcomes in uterine carcinosarcoma and grade 3 endometrial cancer patients: a comparative study.
Zhu J; Wen H; Bi R; Wu X
J Gynecol Oncol; 2016 Mar; 27(2):e18. PubMed ID: 26463439
[TBL] [Abstract][Full Text] [Related]
15. Uterine carcinosarcoma: A review of the literature.
Cantrell LA; Blank SV; Duska LR
Gynecol Oncol; 2015 Jun; 137(3):581-8. PubMed ID: 25805398
[TBL] [Abstract][Full Text] [Related]
16. Endometrioid carcinomas of the uterine corpus with sex cord-like formations, hyalinization, and other unusual morphologic features: a report of 31 cases of a neoplasm that may be confused with carcinosarcoma and other uterine neoplasms.
Murray SK; Clement PB; Young RH
Am J Surg Pathol; 2005 Feb; 29(2):157-66. PubMed ID: 15644772
[TBL] [Abstract][Full Text] [Related]
17. Undifferentiated Endometrial Carcinoma, an Immunohistochemical Study Including PD-L1 Testing of a Series of Cases From a Single Cancer Center.
Al-Hussaini M; Lataifeh I; Jaradat I; Abdeen G; Otay L; Badran O; Abu Sheikha A; Dayyat A; El Khaldi M; Ashi Al-Loh S
Int J Gynecol Pathol; 2018 Nov; 37(6):564-574. PubMed ID: 30059455
[TBL] [Abstract][Full Text] [Related]
18. Identification of distinct molecular subtypes of uterine carcinosarcoma.
An Y; Wang H; Jie J; Tang Y; Zhang W; Ji S; Guo X
Oncotarget; 2017 Feb; 8(9):15878-15886. PubMed ID: 28178664
[TBL] [Abstract][Full Text] [Related]
19. Prognoses and prognostic factors of carcinosarcoma, endometrial stromal sarcoma and uterine leiomyosarcoma: a comparison with uterine endometrial adenocarcinoma.
Akahira J; Tokunaga H; Toyoshima M; Takano T; Nagase S; Yoshinaga K; Tase T; Wada Y; Ito K; Niikura H; Yamada H; Sato A; Sasano H; Yaegashi N
Oncology; 2006; 71(5-6):333-40. PubMed ID: 17690557
[TBL] [Abstract][Full Text] [Related]
20. Executive summary of the American Radium Society® Appropriate Use Criteria for management of uterine carcinosarcoma.
Elshaikh MA; Modh A; Jhingran A; Biagioli MC; Coleman RL; Gaffney DK; Harkenrider MM; Heskett K; Jolly S; Kidd E; Lee LJ; Li L; Portelance L; Sherertz T; Venkatessan AM; Wahl AO; Yashar CM; Small W
Gynecol Oncol; 2020 Aug; 158(2):460-466. PubMed ID: 32475772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]